WEKO3
インデックスリンク
アイテム
Hepatocyte growth factor and Met in drug discovery
https://doi.org/10.24517/00027471
https://doi.org/10.24517/00027471279a8134-4037-4ce0-98e2-e6ab9393727a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
CA-PR-SAKAI-K-271.pdf (1.0 MB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-10-05 | |||||||||
| タイトル | ||||||||||
| タイトル | Hepatocyte growth factor and Met in drug discovery | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| 資源タイプ | journal article | |||||||||
| ID登録 | ||||||||||
| ID登録 | 10.24517/00027471 | |||||||||
| ID登録タイプ | JaLC | |||||||||
| 著者 |
Sakai, Katsuya
× Sakai, Katsuya× Aoki, Shunsuke× 松本, 邦夫 |
|||||||||
| 著者別表示 |
酒井, 克也
× 酒井, 克也
× 松本, 邦夫
|
|||||||||
| 提供者所属 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | 金沢大学がん進展制御研究所 | |||||||||
| 書誌情報 |
Journal of Biochemistry 巻 157, 号 5, p. 271-284, 発行日 2014-12-17 |
|||||||||
| ISSN | ||||||||||
| 収録物識別子タイプ | ISSN | |||||||||
| 収録物識別子 | 0021-924X | |||||||||
| NCID | ||||||||||
| 収録物識別子タイプ | NCID | |||||||||
| 収録物識別子 | AA00694073 | |||||||||
| DOI | ||||||||||
| 関連タイプ | isVersionOf | |||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | 10.1093/jb/mvv027 | |||||||||
| 出版者 | ||||||||||
| 出版者 | Oxford University Press | |||||||||
| 抄録 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Activation of the hepatocyte growth factor (HGF)-Met pathway evokes dynamic biological responses that support the morphogenesis, regeneration and survival of cells and tissues. A characterization of conditional Met knockout mice indicates that the HGF-Met pathway plays important roles in the regeneration, protection and homeostasis of cells such as hepatocytes, renal tubular cells and neurons. Preclinical studies in disease models have indicated that recombinant HGF protein and expression plasmid for HGF are biological drug candidates for the treatment of patients with diseases or injuries that involve impaired tissue function. The phase-I and phase-I/II clinical trials of the intrathecal administration of HGF protein for the treatment of patients with amyotrophic lateral sclerosis and spinal cord injury, respectively, are ongoing. Biological actions of HGF that promote the dynamic movement, morphogenesis and survival of cells also closely participate in invasion-metastasis and resistance to the molecular-targeted drugs in tumour cells. Different types of HGF-Met pathway inhibitors are now in clinical trials for treatment of malignant tumours. Basic research on HGF and Met has lead to drug discoveries in regenerative medicine and tumour biology. © The Authors 2015. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved. | |||||||||
| 著者版フラグ | ||||||||||
| 出版タイプ | AM | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||
